EUVIMEDSkopri EUVIMED
Open access

Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders

Patrick M Vanderboom iD, Yogesh Chawla iD, Surendra Dasari, Isha Kapoor, Shaji K Kumar iD, K Sreekumaran Nair iD, Wilson I Gonsalves iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14246 ↗

At a glance

Journal article in European Journal of Haematology, 2024. Written by Patrick M Vanderboom and 6 co-authors. Institution: Department of Laboratory Medicine and Pathology, Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Extracellular Vesicles, Proteome, Multiple Myeloma, Proteomics. Cited 2 times so far (Crossref); 14 references. The full text is freely available in PubMed Central. Funded by: Marion Schwartz Foundation for Multiple Myeloma, NCI NIH HHS, Mayo Clinic Hematological Malignancies Program.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma‐derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology of MM.

Methods

This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet‐poor peripheral blood plasma of MGUS ( n = 9) and MM ( n = 12) patients using the size exclusion chromatography‐based method and evaluated their proteome using a label‐free proteomics workflow.

Results

In total, 2055 proteins were identified in SEVs, while 2794 proteins were identified in LEVs. The transferrin receptor (or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher in the LEVs derived from MM patients than in MGUS patients.

Conclusions

This study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.

Subjects

MeSH terms (MEDLINE)

Extracellular VesiclesProteomeMultiple MyelomaProteomicsMonoclonal Gammopathy of Undetermined SignificanceHumansMaleFemaleMiddle AgedAgedBiomarkers, TumorPrecancerous ConditionsBiomarkersPrognosis

Author keywords

MGUSexosomemicrovesiclemultiple myelomaproteome

Substances

ProteomeBiomarkers, TumorBiomarkers

Authors and institutions

  • Department of Laboratory Medicine and Pathology, Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • HSR, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Patrick M Vanderboom, Yogesh Chawla, Shaji K Kumar, K Sreekumaran Nair, Wilson I Gonsalves

Funding

  • Marion Schwartz Foundation for Multiple Myeloma
  • NCI NIH HHS
  • Mayo Clinic Hematological Malignancies Program
  • National Center for Advancing Translational Sciences (NCATS)
  • NCATS NIH HHS
  • National Cancer Institute

Cite

APA

Vanderboom, P. M., Chawla, Y., Dasari, S., Kapoor, I., Kumar, S. K., Nair, K. S., & Gonsalves, W. I. (2024). Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders. European Journal of Haematology. https://doi.org/10.1111/ejh.14246

Vancouver

Vanderboom PM, Chawla Y, Dasari S, Kapoor I, Kumar SK, Nair KS, et al. Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders. European Journal of Haematology. 2024. doi:10.1111/ejh.14246

BibTeX
@article{Vanderboom2024,
  author = {Vanderboom, Patrick M and Chawla, Yogesh and Dasari, Surendra and Kapoor, Isha and Kumar, Shaji K and Nair, K Sreekumaran and Gonsalves, Wilson I},
  title = {Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14246}
}
Start for free →